How GcMaf could be helpful :  

1. Activation of macrophages, which play a crucial role in repairing central nervous system (CNS) lesions.
2. Reduction of chronic inflammation, a significant factor in the progression of MS.
3. Regulation of the immune system, potentially preventing immune dysregulation seen in MS.
4. Neuroprotective effects, supporting the survival and function of neurons.
5. Improvement in motor function, as observed in some case studies.
6. 6. Reduction of oxidative stress, which contributes to neuronal damage in MS.
7. Enhancement of phagocytic activity of macrophages, aiding in the clearance of cellular debris and toxic proteins.
8. Promotion of neurogenesis, beneficial in neurodegenerative conditions like MS.
9. Reduction of TNF-alpha levels, a cytokine involved in neuroinflammation and synaptic dysfunction.
10. Support for blood-brain barrier integrity, preventing harmful substances from entering the brain.
11. Reduction of demyelination, a hallmark of MS.
12. Improvement in cognitive function in patients with neurodegenerative diseases.
13. Reduction of neurotoxicity by clearing toxic proteins and supporting neuronal health.
14. Anti-apoptotic effects, preventing programmed cell death of neurons.
15. Overall support for brain health, contributing to slowing the progression of MS

Case Report : GcMAF Treatment in a Patient with Multiple Sclerosis : An Australian male developed MS confirmed by lumbar puncture and magnetic resonance imaging (MRI) scan of the brain in 1989 at the age of 45. He was confined to a wheelchair for four years. 

In 1991, he was treated with pulse steroid therapy to manage symptoms, such as increasing weakness, sensory disturbance, numbness and tingling paresthesia. In 1999, a further episode occurred and then he again received pulse steroid therapy. In 2004, MRI scans showed extensive lesions in the brain and spinal cord, indicating secondary progressive MS. From February 2011, he again became wheelchair-bound and was no longer able to work. At the time, he presented with chronic urinary tract infection, urinary incontinence, severe muscle weakness, muscle pain, head fullness, tinnitus, poor memory, irritability and constipation. From September 17, 2014, he received 0.5 ml GcMAF (1,500 ng/0.5 ml) intramuscularly or subcutaneously twice weekly. After three weeks of treatment with GcMAF, the following beneficial responses and changes were observed; (a) He slept through the night and got up at 7 am to use the bladder. (b) All medications for pain and urinary bladder control and antibiotics had been discontinued. (c) He had more energy and was able to drive an adapted car. (d) He went to work every day. However, he still had some confusion.  

 By October 31, 2014, the responses to GcMAF treatment after six weeks were observed as follows (Figure 1); (i) The patient was able to walk with assistance for the first time after four years being wheelchair-bound, although leg muscles were small and weak due to being confined to a wheelchair for four years. Moreover, he could also go up and down stairs.. He had complete urinary bladder control without medication, even for bladder infections. . Brain fog was much better and he was animated and happy. 

 Subsequently, the patient was continuing treatment with GcMAF 0.5 ml, three times weekly. https://ar.iiarjournals.org/content/36/7/3771.short